Test Price
2,800 AED✅ Home Collection Available
CACNA1C Gene Brugada Syndrome Type 3 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited Next-Generation Sequencing (NGS) with full CACNA1C gene coverage for definitive Brugada syndrome type 3 molecular diagnosis.
- VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM with DHA-licensed phlebotomists and ISO-certified logistics.
- Post-Test Genetic Counselling – Telephonic result interpretation and risk stratification provided by a DHA-licensed Consultant Medical Geneticist.
- Insurance Direct Billing – Pre-authorization and coverage verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The CACNA1C Gene Brugada Syndrome Type 3 Genetic Test employs Next-Generation Sequencing (NGS) on the Illumina platform to detect pathogenic variants in the CACNA1C gene. This analysis confirms the molecular diagnosis of Brugada syndrome type 3, an inherited cardiac channelopathy that predisposes individuals to life-threatening ventricular arrhythmias. Full gene sequencing identifies single nucleotide variants, small insertions and deletions, and copy number alterations with 99.9% sensitivity.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity, full gene coverage including intronic regions | ~95% sensitivity, limited to known hotspot exons |
| Methodology | ISO 9001:2015-certified NGS (Illumina platform) | Capillary electrophoresis, non-ISO lab environment |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Variant Detection | SNVs, indels, CNVs, splice-site variants | Known point mutations only |
Physician Insight & Safety Protocols
“A pathogenic variant in CACNA1C establishes a clear molecular predisposition to Brugada syndrome type 3, but genotype-positive status must always be correlated with a 12-lead ECG, Holter monitoring, and detailed family history. This test enables precise risk stratification and cascade screening for at-risk relatives. I strongly advise every patient to review their results with an electrophysiologist to integrate genetic findings into a comprehensive clinical management plan.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Important: Do not stop, start, or alter any prescribed cardiac medications—including antiarrhythmics or beta-blockers—without direct authorization from your treating physician. Sudden changes may increase the risk of arrhythmic events.
Safety Exclusion Criteria
- Acute febrile illness or active infection at time of blood draw
- Blood transfusion received within the past 4 weeks
- Known hematological malignancy that may interfere with DNA extraction
- Inability to provide informed consent (legal guardian consent required for minors per Federal Decree-Law No. 4 of 2016 on Medical Liability)
Emergency Red Flags – Seek Immediate Medical Attention If:
- Unexplained syncope (fainting), seizure-like episodes, or nocturnal gasping
- Palpitations accompanied by chest pain, dizziness, or shortness of breath
- Family history of sudden cardiac death before age 40
Patient FAQ & Clinical Guidance
1. What does the CACNA1C gene test detect?
This NGS-based test identifies pathogenic mutations in the CACNA1C gene that cause Brugada syndrome type 3, a hereditary cardiac channelopathy. It detects single nucleotide variants, small insertions and deletions, and copy number changes across the entire gene. A positive result confirms the molecular diagnosis and supports cascade screening of first-degree relatives. A negative result reduces but does not eliminate clinical suspicion; ECG criteria and family history remain essential for comprehensive risk assessment.
2. How should I prepare for the blood collection?
No fasting or medication adjustments are required. A simple peripheral blood draw is performed by our DHA-licensed mobile phlebotomist at your location between 8 AM and 11 PM using an ISO-certified cold-chain transport kit. Please bring a valid Emirates ID, complete the consent form, and provide a brief clinical history questionnaire. Inform the phlebotomist if you are taking anticoagulants. Pre-test genetic counselling is included at no additional cost.
3. Will my health insurance cover this genetic test in the UAE?
Most UAE health insurers provide coverage for genetic testing of Brugada syndrome when medically justified and supported by a cardiologist referral. Our team assists with pre-authorization and direct billing verification via WhatsApp at +971 54 548 8731. Coverage is plan-dependent; we recommend checking your policy’s genetic testing clause. All genetic data is handled in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
4. What is the turnaround time for results?
Results are delivered within 3 to 4 weeks from sample receipt. This timeline accounts for DNA extraction, library preparation, NGS sequencing on the Illumina platform, bioinformatic analysis, variant interpretation, and clinical validation by our Consultant Medical Geneticist. A detailed report with variant classification per ACMG guidelines is provided digitally and in print.
5. How is my genetic data protected?
Your genetic information is securely stored and processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Only you and your designated healthcare provider can access the results. Data is encrypted and never shared with third parties without your explicit written consent.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed under the regulatory oversight of the Dubai Health Authority (DHA) and adheres to all applicable UAE federal laws governing medical practice and patient data protection. Patient confidentiality and data security are maintained in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and informed consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. All laboratory processes are ISO 9001:2015 certified and subject to regular DHA audit.
Clinical & Logistical Metadata
| Test Name | CACNA1C Gene Brugada Syndrome Type 3 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA tube) |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina Platform, ISO 9001:2015 |
| ICD-10-CM Code | I49.8 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | DHA Facility License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians